Wirral Clinical Commissioning Group

North West Commissioning Support Unit

This Patient Group Direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction

for the administration of

EMLA Cream 5%

by registered **Nurse** to

produce surface anaesthesia of the skin prior to a medical procedure involving needle insertion

Version number: EMLA PGD 2015 v1

PGD Development- EMLA Cream 5% to produce surface anaesthesia prior to a medical procedure involving needle insertion

	Name	Job title	Organisation
Lead author	Helen Dingle	Prescribing Adviser	North West CSU
Lead doctor (or dentist)			
Lead pharmacist	Caroline Crouch	Medicines Management Pharmacist	North West CSU
Representative of other professional group using PGD			

PGD Signatories

PGD signatories-	
Lead Doctor	Name: Dr Saket Jalan Position: CCG Prescribing Lead Signature: Date:
Lead Pharmacist	Name: Steve Riley Position: Senior Prescribing Adviser Signature: Date:
Lead Nurse	Name: Sue Smith Position: Lead Nurse Quality and Patient Safety Signature: Date:

PGD Authorisation

Organisational Authorisation by	Name: Lorna Quigley Position: Director of Quality and Patient Safety Signature: Date:
Optional local Signatory	Name: Position: Signature: Date:

Training and competency of registered health Professionals

	Requirements of registered health professionals working under the PGD
Qualifications and professional registration	Registered Nurse having valid registration with the Nursing and Midwifery Council (NMC) and working within Wirral CCG The nurse will have due regard for the NMC Code of Conduct, Scope of Professional Practice and Standards of Administration for nurses
Initial training	• Received training to undertake supply and administration of medicines under Patient Group Directions. • Received specific training in the use of this PGD • The nurse should have achieved the competency levels specified in the NICE Competency Framework for Health Professionals using Patient Group Directions
Competency assessment	Maintenance of own level of updating with evidence of continued professional development (PREP requirements)
Ongoing training and competency	• Annual update on resuscitation skills and the management of anaphylaxis in the community. • Able to provide evidence of continued professional development i.e. meeting Post-Registration Education & Practice (PREP) requirements

Change history

Version number	Change details	Date
May 2015	Reviewed to • BNF May 2015 accessed 13 May 2015 • Summaries of Product Characteristics SPCs in the Electronic Medicines Compendium eMC	13/05/2015

Clinical condition

Clinical condition or situation to which this PGD applies	Local anaesthetic for topical use to produce surface anaesthesia of the skin prior to a medical procedure involving needle insertion
Inclusion criteria	• Individual undergoing a medical procedure involving painful needle insertion • Valid consent
Exclusion criteria	• Known hypersensitivity to anaesthetics of the amide type or any component of EMLA cream • Individuals with anaemia,glucose-6-phosphate dehydrogenase deficiency or hereditary or idiopathic methaemoglobinaemia or patients on concomitant therapy known to produce such conditions e.g. sulphonamides • Prior to injections of intracutaneous live vaccines • No valid consent
Cautions (including any relevant action to be taken)	• EMLA cream contains polyoxyethylene hydrogenated castor oil which may cause skin reactions • Do not store above 30°C, do not freeze
Arrangements for referral for medical advice	If deferred ensure arrangements are put in place for a further appointment.
Action to be taken if the patient is excluded	If excluded refer to GP for advice and treatment.
Action to be taken if the patient declines treatment.	If declines, discuss with patient and refer to GP for treatment if necessary. If procedure continues without EMLA Cream, obtain written refusal and record in notes. Document refusal.

Details of the medicine

Name, form and strength of medicine	EMLA Cream 5% (Lidocaine 2.5%, Prilocaine 2.5%)
Legal category	GSL
Black triangle	No
Indicate any off-label use (if relevant)	N/A
Route/method of administration and dose	Topical application of approximately 2g. (approx half a 5g tube) EMLA Cream 60 minutes prior to the procedure, applied under occlusive dressing. For babies and children up to the age of 12, the maximum dose is 1.0g/10cm^2. Not to be applied to wounds, mucous membranes or areas of atopic dermatitis or to genital mucosa or eyes or ears.
Dose and frequency	As above and as a single dose. Maximum treatment period 1 hour.
Quantity to supply/administer	One dose
Adverse effects	Transient paleness, redness and oedema have been reported. In rare cases local anaesthetics have been associated with allergic reactions including anaphylactic shock. Rare cases of discrete local lesions at the application site in children with atopic dermatitis or mollusca contagiosa Corneal irritation after accidental eye exposure
Drug Interactions Please refer to current SPC or BNF for full details	Methaemoglobinaemia may be accentuated in patients on concomitant therapy known to produce such conditions e.g. sulphonamides Cardiac effects of anti-arrhythmic drugs such as amiodarone may be additive
Records to be kept	Record fully in clinical record / GP records and as required in patient held records • State PGD has been followed and record treatment plan, including dose and route of administration in patient's notes • Patient's name and date of birth • Date and time given • Brand, batch and expiry date of products used • Signature and name of the person supplying or administering the medication • Advice given • An electronic or manual record of all individuals receiving treatment under this PGD should be kept for audit purposes. • Any serious adverse events that may be attributable to any product named in this PGD, should be reported to the MHRA using the yellow card system and documented in the medical records. The GP should also be informed.

Patient information

Information to be given to patient or carer	• Care should be taken to avoid EMLA Cream coming into contact with the eyes, if contact with eyes occurs, immediately rinse the eye with water • Care should be taken to avoid EMLA Cream coming into contact with the middle ear • Numbness will last for several hours, contact practice if sensation does not return to affected area • Advise on possible side effects and their management

Appendices

Appendix A Key references

1. Summary of Product Characteristics for Emla 5% Cream
   http://www.medicines.org.uk/emc/search
2. Current BNF chapter 15.2
   https://www.medicinescomplete.com/mc/bnf/current/index.htm
3. NICE Good Practice Guidance on Patient Group Directions and the Competency framework for healthcare professionals using Patient Group
   http://www.nice.org.uk/mpc/goodpracticeguidance/GPG2.jsp

Appendix B

Health professionals' agreement to provide EMLA Cream 5% to produce surface anaesthesia prior to a medical procedure involving needle insertion

Practitioner	I have read and understood the Patient Group Direction and agree to supply and/or administer this medicine only in accordance with this PGD
Name	
Signature	
Date	

Senior Representative (Clinical)	I give authorisation on behalf of Wirral CCG for the named Health Care Professional who has signed this PGD to administer the medication as prescribed within this direction.
Name	
Signature	
Date	